Proxy Blog

Regeneron Pharmaceuticals, Inc.

May 19, 2020

The annual proxy for this pharmaceutical company had the following proposals: 

  1. Proforma proposals on directors, appointment of auditors, and “say-on-pay” advisory vote 
  2. Board proposal on incentive plan 

Magni voted as follows: 

  1. For and against proforma proposals.
    For directors – The disclosures in the proxy meet the criteria in Magni’s policy on election of directors.
    -For auditors – The company meets the criteria in Magni’s policy on auditor ratification.
    -Against “say-on-pay” – The disclosures in the proxy do not meet the criteria in Magni’s policy on the advisory vote as the company is smaller than the average of the companies in the peer group 
  2. For board proposal on incentive plan – Stock plans align the interests of the board and management team with the shareholders.